Key result
Combined ST2 and CRP elevation linked to ~5-fold higher mortality in chronic HF.
Why the study?
ST2 has emerged as a marker of inflammation, fibrosis, and cardiac stress, but its prognostic value combined with CRP in chronic heart failure compared to classical markers was unclear.
Does the combination of ST2 and CRP predict mortality better than individual markers in patients with chronic heart failure?
Population
178 patients with chronic heart failure
Comparison
Combination of ST2 and CRP vs individual assessment of ST2, CRP, NT-proBNP, hs-cTnT, and clinical parameters
Design
Cohort study
Authors
Loading...
ST2-CRP combination was associated with higher mortality in chronic HF; supports larger prospective validation before clinical risk stratification use.
Cohort (n=178)
No
Does the combination of ST2 and CRP predict mortality better than individual markers in patients with chronic heart failure?
Hazard Ratio: 5.158 (95% CI 2.33–11.41)
p-value: p=<0.0001
The combined measurement of ST2 and CRP identifies a high-risk subgroup of chronic heart failure patients, providing valuable prognostic information for mortality risk.
Dupuy et al. (2016) conducted a cohort in Chronic heart failure (n=178). Combined elevation of ST2 and CRP vs. Low ST2 and low CRP was evaluated on All-cause mortality (HR 5.158, 95% CI 2.33-11.41, p=<0.0001). The combined elevation of ST2 and CRP significantly predicted worsened outcomes and increased the risk of all-cause mortality in patients with chronic heart failure (HR 5.158).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: